Revive Therapeutics Ltd - Ordinary Shares

News & Events

Press Releases

In The Media

1. Revive Therapeutics Announces Proposed Shares for Debt Transaction

   GlobeNewswire APR 21, 2025 4:30 PM EDT
   TORONTO, April 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or t...
   READ ARTICLE

2. Revive Therapeutics to Investigate Bucillamine's Potential in Cancer Treatment

   GlobeNewswire APR 10, 2025 7:00 AM EDT
   TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or t...
   READ ARTICLE

3. Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program

   GlobeNewswire APR 1, 2025 7:30 AM EDT
   TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or t...
   READ ARTICLE

4. Revive Therapeutics Announces Results of Annual Shareholder Meeting

   GlobeNewswire MAR 19, 2025 9:14 AM EDT
   TORONTO, March 19, 2025 (GLOBE NEWSWIRE) --  Revive Therapeutics Ltd. (“Revive”...
   READ ARTICLE

5. Revive Therapeutics Announces LOI to Acquire DiagnaMed's Molecular Hydrogen Program

   GlobeNewswire MAR 3, 2025 8:00 AM EST
   TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- TORONTO, March 3, 2025 – Revive Therapeutics L...
   READ ARTICLE

6. Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

   GlobeNewswire FEB 3, 2025 5:00 PM EST
   TORONTO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or th...
   READ ARTICLE

7. Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

   GlobeNewswire JAN 8, 2025 7:30 AM EST
   TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or th...
   READ ARTICLE

8. Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke

   GlobeNewswire NOV 12, 2024 7:45 AM EST
   TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or th...
   READ ARTICLE

9. Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

   GlobeNewswire OCT 31, 2024 7:30 AM EDT
   TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or th...
   READ ARTICLE

10. Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

    GlobeNewswire SEP 18, 2024 7:00 AM EDT
    TORONTO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or t...
    READ ARTICLE